ERBB2 and breast carcinoma: T-DM1 has proven in a phase IIIB Kamilla trial that it has good activity and is well tolerated in patients presenting with brain metastases from HER-2-positive breast cancer (overall response rate and clinical benefit rate were 21.4%) [49].